Research Article
Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods
Table 3
CTC positivity (number of cases and percentage) by ScreenCell stratified according to clinical settings and timepoints.
| | Clinical setting | CTC+ (%) at baseline
(T0) | CTC+ (%) after the 1st cycle of therapy
(T1) | CTC+ (%) after the 2nd cycle of therapy
(T2) |
| | M0 | 11/13 (84.6%) | 4/10 (40.0%) | 12/14 (85.7%) | | M+ | 32/38 (84.2%) | 27/30 (90.0%) | 16/17 (94.1%) | | | 22/27 (81.5%) | 20/22 (90.9%) | 16/17 (94.1%) | | | 10/11 (90.9%) | 7/8 (87.5%) | — | | Total | 43/51 (84.3%) | 31/40 (77.5%) | 28/31 (90.3%) |
|
|
